ライフサイエンスコーパス: France

1 (VP250; n = 25; DBV Technologies, Montrouge, France).

2 tization is uncommon (e.g., Germany, Poland, France).

3 d using VITEK 2 (bioMerieux, Marcy-L'Etoile, France).

4 lantation" meeting (June 9-10, 2016, Nantes, France).

5 y commercial ELISA (LISA TRACKER, Theradiag, France).

6 a temperate macrotidal estuary (Gironde, SW France).

7 tudy among physicians and nurses (90 ICUs in France).

8 e forest experimental site of Breuil-Chenue (France).

9 evel: the Necker Children's Hospital (Paris, France).

10 esthesiometry (Luneau Ophthalmologie, Paris, France).

11 e forest ecosystem of Montiers (Northeastern France).

12 FibroScan 502 Touch device (Echosens, Paris, France).

13 editerranean subtidal rocky shores (Corsica, France).

14 selected from a German longitudinal cohort (FRANCES).

15 ansplanted patients between 2006 and 2010 in France.

16 urce of all surgical procedures performed in France.

17 CUs of two teaching hospitals in Paris area, France.

18 uvir plus simeprevir for 12 weeks) in Paris, France.

19 flow between southwest Britain and northwest France.

20 e Agriculture and Cancer (AGRICAN) cohort in France.

21 om a tuberculosis household contact study in France.

22 outbreaks of plague, from 1722 in Marseille, France.

23 dmitted to Lille University Hospital, Lille, France.

24 rospectively included all TAVRs performed in France.

25 ith usual care at 10 university hospitals in France.

26 ngle-arm, phase 2 trial at five hospitals in France.

27 the La Voulte exceptional fossil biota in SE France.

28 omes Neurologiques Paraneoplasiques in Lyon, France.

29 bute to the epidemiology of HEV infection in France.

30 es found deep in Bruniquel Cave in southwest France.

31 at 60 hospitals in the Netherlands, UK, and France.

32 985; of these, 3172 patients were treated in France.

33 ssion and on the morbidity of HCV in PWID in France.

34 dborne infection and a notifiable disease in France.

35 of prevalent NAPD cases in an urban area in France.

36 ly 2014 in 15 intensive care units (ICUs) in France.

37 f patients with type 2 diabetes recruited in France.

38 e patients were included from 864 centers in France.

39 ve at a euro50,000/QALY threshold was 47% in France.

40 blast cells) were enrolled at six centres in France.

41 innovative surgery to a development phase in France.

42 were produced by 25 hospital laboratories in France.

43 ogy, Salpetriere University Hospital, Paris, France.

44 ond 6 months of ART between 1997 and 2011 in France.

45 icated with myocarditis imported in Mainland France.

46 in 2012-2014 in poor districts of Marseille, France.

47 University Hospital of Rennes, France.

48 AR over 10 years in an urban area in central France.

49 he results obtained from 70 living donors in France.

50 elop a modified cardiac allocation system in France.

51 he Claude Bernard-Lyon 1 University in Lyon, France.

52 to the colder climate in Britain compared to France.

53 ampled periodically over 12 years in western France.

54 for PAR, with or without concomitant AA, in France.

55 ied names, we can detect academic couples in France.

56 Fifteen university and nonuniversity ICUs in France.

57 lar trends were observed for US youth and in France.

58 ct of expert review of lymphoma diagnosis in France.

59 cardiac intensive care units in metropolitan France.

60 -based case-control studies from Denmark and France.

61 +/- 7.1 years) diagnosed with RP, living in France.

62 waters sampled at the puy de Dome station in France (1465 m) were screened for their ability to produ

63 urther compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2

64 mpared with 8.2% and 10.1%, respectively, in FRANCE 2 (p < 0.001 for both).

65 fined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001).

66 nts from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis.

67 clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards)

68 The FRANCE-2 registry prospectively included all TAVRs perfo

69 The FRANCE-2 registry represents the largest database availa

70 d Coronary Heart Disease (RECORD) GPS Study, France, 2012-2013; 6,313 trips made by 227 participants)

71 re collected (Australia, 74; Canada, 48; and France, 209).

72 netic testing for melanoma-prone mutation in France, a country with low to moderate incidence of mela

73 In France, a higher priority status is granted to transplan

74 Among critically ill elderly patients in France, a program to promote systematic ICU admission in

75 with GBS from Birmingham, U.K., and Garches, France, admitted between 1998 and 2013.

76 s now the most important genetic disorder in France, affecting one birth for every 2,400, and one of

77 d's first partial face transplant in Amiens (France) after a dog attack had left her face severely di

78 arrying the Val30Met mutation also living in France, all referred to and followed at the French Natio

79 Local regulatory authorities in France allowed inclusion of up to four children in this

80 Nine centers in France analyzed 204 patients undergoing PD to NJEEN (n =

81 86,829 in the real-life monitoring group) in France and $11,965 ($93,795 vs. $81,829) in the United S

82 The ICER was $1,754 per LYG in France and $32,415 per LYG in the United States.

83 om a tuberculosis household contact study in France and a replication study in families from South Af

84 or the United Kingdom, Ireland, and northern France and also suggest that current dynamical model for

85 deployed at four different coastal areas in France and analyzed using liquid chromatography coupled

86 tumors, at 28 intensive care units (ICUs) in France and Belgium between August 12, 2013, and January

87 out PVT were enrolled from 43 liver units in France and Belgium between June 2000 and March 2006.

88 western Europe where prison suicide rates in France and Belgium were more than 100 per 100 000 prison

89 Twenty-nine ICUs in France and Belgium.

90 d countries (USA, UK, Germany, Japan, Italy, France and Canada) were the most prolific during the fir

91 tario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Ca

92 tario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Ca

93 he rule of 3 to recommend genetic testing in France and countries with low to moderate incidence of m

94 sanguineous Angolan kindred, who was born in France and developed disseminated E. dermatitidis diseas

95 Patients were enrolled in France and England and treated between December 2010 and

96 ype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine

97 HEV is endemic in France and hyperendemic in some areas; eating habits alo

98 four parallel groups at 13 memory centres in France and Monaco.

99 d to individuals born in natural reserves in France and Mongolia.

100 ts of transfused SCD patients were combined (France and The Netherlands).

101 ries with a reported travel destination, and France and the UK receiving the highest number of cases,

102 specialist cancer centres in two countries (France and the USA).

103 perience is a striking contrast with that in France and the USA, which may relate to contamination of

104 stry data of all donors after brain death in France and their organ recipients between 2007 and 2013.

105 0,569 French blood donors living in mainland France and three overseas areas.

106 The mineral was observed in Bidart (France) and Gubbio (Italy), suggesting a widespread phen

107 reprocessing facilities located in La Hague (France) and Sellafield (Great Britain).

108 ), chromID MRSA (bioMerieux, Marcy l'Etoile, France), and CHROMagar MRSA (BD Diagnostics, Sparks, MD)

109 ribution gap in the Bay of Biscay (southwest France), and northward contraction of the southern range

110 dromes Neurologiques Paraneoplasiques (Lyon, France), and participants were 7 consecutive patients di

111 kaya 1 (from Russia) and Le Moustier 2 (from France)-and a recent human sample.

112 ecommendations in both the United States and France, and across all socioeconomic groups.

113 ed at 66 sites in the United States, Canada, France, and Australia between December 2013 and August 2

114 tpatient sites in the United States, Canada, France, and Australia.

115 ean tertiary care centers (Austria, Germany, France, and Belgium).

116 y (1703) at 17 hospitals in the USA, Canada, France, and Germany.

117 ore than male life expectancy, and in Chile, France, and Greece where the two sexes will see similar

118 pitals in England, Scotland, Wales, Germany, France, and Sweden.

119 at 22 centres in the USA, UK, Canada, Spain, France, and the Netherlands.

120 ademic medical centers in Australia, Canada, France, and the United States.

121 of all academics in Italy, researchers from France, and those working at top public institutions in

122 inating from patients in the United Kingdom, France, and Tunisia, were sequenced along with the type

123 The setting was 2 university hospitals in France (at Bordeaux and Dijon) from January 2011 (first

124 In Finland and France atopic children commonly react to seeds of oilsee

125 erches sur le SIDA et les Hipatites Virales (France), Australian National Health and Medical Research

126 er SOT between 2000 and 2014 in 36 European (France, Belgium, Switzerland, the Netherlands, Spain) ce

127 outcomes for acute myocardial infarction in France between 1995 and 2015.

128 2,760 childhood leukemia cases diagnosed in France between 2002 and 2007 (including 2,275 cases of a

129 in a case-control study conducted in eastern France between 2005 and 2010.

130 rence center for primary immunodeficiency in France between 2006 and 2010 were included.

131 d all adult patients operated on with AGB in France between 2007 and 2013.

132 Data of all patients who underwent RPC in France between 2009 and 2012, including demographics, di

133 lyzed 12 patients who received Eculizumab in France between 2010 and 2013 for severe post-HSCT TMA.

134 ogy and 2 departments of medical oncology in France between January 2008 and December 2014.

135 ergency department of one of 24 hospitals in France between January 2012 and April 2015 and were foll

136 TAVRs performed in 48 centers across France between January 2013 and December 2015 were prosp

137 ersity hospitals and one general hospital in France between June 2009 and December 2011.

138 intubation while being treated at 7 ICUs in France between May 2015 and January 2016; there was 28 d

139 t of the University Hospital of Montpellier (France), between September 1996 and July 2015 for a susp

140 cities of Dijon, Bordeaux, and Montpellier, France, between March 1999 and March 2001.

141 of Hopital Europeen Georges-Pompidou, Paris, France, between Sept 1, 2013, and June, 30, 2014.

142 of Directors currently includes members from France, Brazil, and Canada.

143 the University in Toulouse (France), Paris (France), Clermont-Ferrand (France), Liege (Belgium), and

144 sive lip treatment in the United Kingdom and France (clinical trial sample).

145 2), Giessen (Germany; cohort 3), and Paris (France; cohort 4).

146 ed over the Atlantic Ocean, off the coast of France, confirming the ability of the device to detect a

147 In France, consolidating all RPCs to higher volume centers

148 study centres in the USA, Italy, Australia, France, Czech Republic, New Zealand, and Poland enrolled

149 depositional areas along the Rhone River in France, dated, and analyzed for PCDDs and PCDFs.

150 a (IF) brands from local markets from Paris, France; DF, Mexico; Copenhagen, Denmark; England, UK; an

151 escents, and adults in the United States and France.Dietary intakes of individuals aged >/=4 y were r

152 n outbreak of BT virus serotype 8 in central France during 2015 that has continued to spread in Europ

153 ass windows of the Sainte-Chapelle in Paris, France, during its restoration.

154 (Bizerte, Tunisia) and European (Marseille, France) edges of the Western Mediterranean basin is pres

155 novation from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to othe

156 we analyzed 72 pocket Bibles originating in France, England, and Italy and 293 additional parchment

157 conducted at 4 sites in 4 countries (Canada, France, England, and the Netherlands) from which data we

158 s from seven university hospital centres (in France [five], UK [one], and Canada [one]).

159 airs from a population-based birth cohort in France followed from pregnancy to age 5.5 years of the c

160 The substantial improvement in survival in France for newborns born at 25 through 31 weeks' gestati

161 s from seven university hospital centres (in France [four], Switzerland [one], UK [one], and Italy [o

162 atients, collected from 28 centers mainly in France from 2000 and 2014.

163 ohort, recruited from 35 clinical centers in France from 2006 through 2012.

164 lized in 68 neonatal intensive care units in France from April through December 2011.

165 was performed at 4 tertiary care centers in France from August 2005 through December 2012.

166 stitutions in the United States, Canada, and France from January 1, 1980, through December 31, 2010.

167 men) were recruited from hospitals in Paris, France, from 2014 through 2016.

168 erformed at 18 hospitals in Belgium and 2 in France, from February 2010 through February 2013.

169 r NS in a tertiary referral center in Paris, France, from January 1, 1990, through December 31, 2015.

170 from the Institut Gustave Roussy (Villejuif, France; from Jan 1, 1996, to May 15, 2012), Mount Sinai

171 gdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO).

172 apy (AIT) clinical practice was conducted in France, Germany and Spain.

173 nfants from rural areas in Austria, Finland, France, Germany, and Switzerland, for the first year of

174 cardiology in the UK, Netherlands, Belgium, France, Germany, Austria, Denmark, Australia, and New Ze

175 were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, an

176 ivate hospitals in Austria, Belgium, Canada, France, Germany, Greece, Italy, and the USA.

177 n nine countries (Canada, Costa Rica, Egypt, France, Germany, Greece, Italy, New Zealand, and the USA

178 nine countries (n = 726), including Canada, France, Germany, India, Indonesia, Israel, Japan, New Ze

179 ratic Republic of the Congo, Denmark, Egypt, France, Germany, India, Norway, and Thailand) recruited

180 Study (Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norw

181 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, S

182 0 hospitals or clinics in Australia, Canada, France, Germany, Israel, Italy, Spain, and the UK, to as

183 gibility from 52 clinical centres in Canada, France, Germany, Israel, Italy, Spain, the UK, and the U

184 , Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norwa

185 ic, hospital, and private cancer centres) in France, Germany, Italy, and USA.

186 entina, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Nether

187 in variance among the G7 countries (Canada, France, Germany, Italy, Japan, the United Kingdom, and t

188 secondary care centres in Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Romania, Sout

189 in 22 neuromuscular care centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK.

190 11 European study sites in Austria, Belgium, France, Germany, Italy, Spain, and the UK.

191 he USA, Australia, Belgium, Canada, Denmark, France, Germany, Sweden, and the UK).

192 estigator sites across Argentina, Australia, France, Germany, Sweden, and the USA.

193 -controlled study at 35 hospitals in Canada, France, Germany, the UK, and the USA.

194 11 countries (Bangladesh, Brazil, Ethiopia, France, Ghana, Indonesia, Japan, Peru, Thailand, Turkey,

195 pulations now in Canada, Switzerland, Italy, France, Greece, and Hungary.

196 ohorts from 12 countries (Australia, Brazil, France, Greece, Hong Kong, Italy, Japan, Singapore, Spai

197 ton deliveries from 1996 to 2011 in Belgium, France, Greece, Ireland, Italy, the Netherlands, Norway,

198 udies of HIV-positive individuals in Europe (France, Greece, the Netherlands, Spain, Switzerland, and

199 France had the lowest mortality: 39.8/100 000 for males

200 explored shallow underwater cave in Corsica (France) harbouring the largest biomass (by more than 100

201 Since 2000, France has had an active role in development of global h

202 France has the lowest present-day cerebrovascular diseas

203 rgentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, and the USA.

204 public, and private hospitals and clinics in France, Hungary, Italy, Poland, Romania, Spain, Turkey,

205 broplasty was performed by Harve Deramond in France in 1984 due to a hemangioma of cervical vertebral

206 s accidental introduction into South-Western France in 2004, V. velutina has spread to much of wester

207 eterm infants born at <32 wk of gestation in France in 2011.

208 ucted in all maternity and neonatal units in France in 2011.

209 sing 23 rose wines from Australia, China and France in three major cities in China.

210 uited from Oxford, Truro (UK), and Toulouse (France), including 44 immune-competent patients with acu

211 eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA).

212 ure also increases during this age period in France irrespective of age at transplantation.

213 The cardiac allocation system in France is currently based on urgency and geography.

214 s treated in 9 skin cancer centers in Spain, France, Italy, and Austria.

215 a crossover study done in medical centres in France, Italy, and the Netherlands, patients aged 18-69

216 in four epilepsy surgery centres, in Brazil, France, Italy, and the USA.

217 In the Europe-4 countries (Germany, France, Italy, and United Kingdom), there are approximat

218 oss Europe (Norway, Estonia, United Kingdom, France, Italy, Greece, and Spain), full dietary data wer

219 pathologist, from seven countries (Denmark, France, Italy, Japan, Netherlands, Portugal, and the UK)

220 d ZIKV reported in Argentina, Canada, Chile, France, Italy, New Zealand, Peru, Portugal, and the USA.

221 ss-cultural dataset (N = 1,368 from Finland, France, Italy, Russia, and the United Kingdom).

222 g with MCOR in six families originating from France, Japan, and Mexico.

223 discoveries in Cretaceous amber from Canada, France, Japan, Lebanon, Myanmar, and the United States [

224 mmercially available Etest((R)) (Biomerieux, France) kit.

225 (France), Paris (France), Clermont-Ferrand (France), Liege (Belgium), and Monza (Italy).

226 rmany); CNSA, INSERM, MiRe-DREES, and IRESP (France); Ludvig and Sara Elsass Foundation, The Spastics

227 d Research, University Claude Bernard (Lyon, France), Malaria Research and Training Centre (Bamako, M

228 n = 3), international organizations (n = 2), France (n = 2), Poland (n = 1), Australia (n = 1), Mexic

229 n eligible children, the four youngest, from France (n=2), Italy (n=1), and Greece (n=1), aged 20, 26

230 y (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland.

231 on analyses in separate series from Algeria, France, Norway, and North America (n=263) supported this

232 ly2019Ser carriers originating from Algeria, France, Norway, and North America.

233 VIDAS(R) system (bioMerieux, Marcy l'Etoile, France) obtaining a fluorescence enhancement of about 50

234 nducted in 8 comprehensive stroke centers in France (October 2015-October 2016).

235 were 22,270 brain-dead patients diagnosed in France, of whom 161 with extracorporeal membrane oxygena

236 oVascular Clinical Trialists Forum in Paris, France, on December 6, 2013.

237 nnay grapevines in the Languedoc-Roussillon (France) over two years.

238 ts affiliated to the University in Toulouse (France), Paris (France), Clermont-Ferrand (France), Lieg

239 iliated hospitals and 9 general hospitals in France participated.

240 0 centres in four countries (Czech Republic, France, Poland, and the USA).

241 m seven north-east Atlantic Ocean locations (France, Portugal, Continental Spain, Canary Islands, and

242 ov., from Early Cenomanian La Buzinie amber (France), preserved with its marsupial pouch and content.

243 ntrations were also available for the Ile-de-France region (including Paris).

244 the association was reinforced in the Ile-de-France region when this indicator was combined with benz

245 6 cases from Quebec City (Canada) and Paris (France), respectively.

246 versal goal, understanding and acknowledging France's history could help strengthen advocacy in favou

247 structure was supposed to bring metropolitan France's model of universal and free public health care

248 e study of crop production in a catchment in France showed that, compared to the current method, TNT2

249 tancy in South Korea is followed by those in France, Spain, and Japan.

250 ional prospective cohort study, conducted in France, Spain, Belgium, and Switzerland between May and

251 ls with specialised diabetic foot clinics in France, Spain, Italy, Germany, and the UK.

252 d from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.

253 als and cancer centres in Australia, Canada, France, Spain, the UK, and the USA.

254 hern Portugal, northwest Ireland and Britain/France; subsequent hierarchical analysis of population s

255 gium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy, Spain, and the USA, pati

256 mber 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantat

257 increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001).

258 A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were includ

259 y rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively,

260 FRANCE TAVI participants were older but at lower surgica

261 The FRANCE TAVI registry provided reassuring data regarding

262 More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR.

263 Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).

264 anaidaceans from the Cretaceous of Spain and France that provide conclusive evidence for marsupial ca

265 d 2,723 controls from 3 PD studies (Denmark, France) that obtained information on smoking through int

266 surgery at the University Hospital of Lille, France (the Lille Bariatric Cohort).

267 rica, Germany, Switzerland, Netherlands, and France, the meeting was well attended.

268 5 European countries (Belgium, Switzerland, France, the Netherlands and the United Kingdom) and esti

269 hase 3 trial (METOP) at 16 sites in Germany, France, the Netherlands, and the UK.

270 gistry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom) aim

271 gistry of Crossboss and Hybrid procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom) reg

272 gistry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom, REC

273 for a series of case study regions (western France, the western Alps, and the Czech Republic and Slo

274 ansplant recipients younger than 30 years in France, those currently in adolescence or early adulthoo

275 famous water frogs (Pelophylax) in southern France, through a fine-scale genetic survey.

276 Here we extrapolate from the situation in France to quantify the potential invasion of V. velutina

277 stitute Mediterranee Infection in Marseille, France, to illustrate the value of expert protocols feed

278 ented the most common bariatric procedure in France until 2010.

279 en by climate change and land use change for France up to the year 2100 by taking interactions betwee

280 The prevalence in France was 1.8 per million.

281 France was partitioned into 300 iso-populated units, i.e

282 orer; SuperSonic Imagine SA, Aix-enProvence, France) was used than when an SL15-4 probe (Aixplorer) w

283 patients from University Hospitals of Lyon, France, was used to calculate the endovascular distances

284 air quality measurement data from the UK and France, we demonstrate that road traffic exhaust has a f

285 are estimated to amount to 12500 per year in France, we herein decided to compare the empirical clini

286 paper, the second in The Lancet's Series on France, we look at how this tension has evolved.

287 tric cancer surgery between 2010 and 2012 in France were included (N = 11,196).

288 with reconstruction between 2010 and 2012 in France were included (n = 3286).

289 erwent EC resection between 2010 and 2012 in France were included in this nationwide study (n = 3009)

290 ll SCAs occurring in public places in Paris, France, were prospectively collected between 2000 and 20

291 nducted in the Gironde estuary (southwestern France) where PFASs were ubiquitously detected albeit at

292 ss in common garden experiments conducted in France, where accessions are enriched in hydroxyalkenyls

293 be severely and negatively affected (Berce, France), while populations at the contemporary northern

294 er Paris Area, the most populated regions in France with about 12 million inhabitants.

295 d eight female silver eels from the south of France with pop-up satellite tags during escapement from

296 n an independent cohort of 626 patients from France with stage I-III clear cell renal cell carcinoma

297 UK, Germany, Finland, Australia, Sweden, and France), with biomarkers sampled between 1970 and 2010.

298 2015, to July 14, 2016, on the west coast of France, with GPs in 801 practices participating and invo

299 ngle-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals.

300 e (UHI) Mediterranee Infection of Marseille, France, with the support of recent or representative stu